Propanc Biopharma (PPCB) Operating Leases (2019 - 2025)

Propanc Biopharma (PPCB) posted quarterly Operating Leases of $35249.0 for Q4 2025, down 16.23% quarter-over-quarter from $42080.0 in Q3 2025.

Propanc Biopharma (PPCB) Operating Leases (2019 - 2025) Analysis & Trends

Propanc Biopharma (PPCB) has reported Operating Leases for 6 consecutive years, with $35249.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Operating Leases changed N/A year-over-year to $35249.0; the TTM figure through Dec 2025 stood at $35249.0 (changed N/A YoY), while the FY2025 annual figure was $41749.0, changed N/A from the prior year.
Operating Leases slipped to $35249.0 in Q4 2025 per PPCB's latest filing, from $42080.0 in the prior quarter.
Across five years, Operating Leases topped out at $42319.0 in Q2 2022 and bottomed at $1942.0 in Q1 2024.
Historically, Operating Leases has averaged $27181.0 across 4 years, with a median of $30885.0 in 2022.
Annual changes were most pronounced in 2023 — Operating Leases slumped 54.45% — and 2024, when it tumbled 92.21%.
Propanc Biopharma's Operating Leases stood at $30885.0 in 2022, then sank by 73.96% to $8041.0 in 2023, then tumbled by 75.85% to $1942.0 in 2024, then surged by 1715.09% to $35249.0 in 2025.
Business Quant data shows PPCB's Operating Leases at $35249.0 in Q4 2025, $42080.0 in Q3 2025, and $41749.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Propanc Biopharma	587,855.41	587,855.41	-

Download Data